Michael Hutton joined Eli Lilly as Chief Scientific Officer for Neurodegenerative Disease in 2009 and was promoted to his current position Vice President Neurodegeneration Research, in 2018. He is now based at Lilly Research Laboratories in Indianapolis and leads Lilly’s drug discovery for Alzheimer’s Disease, Parkinson’s Disease, ALS and related monogenic disorders. Lilly’s Neurodegeneration Disease Portfolio currently has seven experimental therapies in clinical development that target amyloid, tau and other genetically validated targets. More recently genetic medicines have been added to the Portfolio for both common and monogenic indications. Prior to joining Lilly, Dr Hutton worked at Merck (2 years) and at the Mayo Clinic Jacksonville as Professor of Neuroscience (11 years). During his time at the Mayo Clinic, Dr Hutton’s team played a major role in determining the causes of Fronto-temporal Dementia with the discovery mutations in tau (MAPT) and progranulin (GRN) and the mechanism by which these lead to neurodegeneration. He received the Potamkin (2000) and Metlife (2001) Prizes for his work on Alzheimer’s Disease and Fronto-temporal Dementia. Dr Hutton has published over 200 papers in peer reviewed journals and is a regular speaker at international conferences on neurodegenerative conditions.